• Clinical Insights: September 30, 2019

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Jynneos™ (smallpox and monkeypox vaccine, live, nonreplicating) – New Vaccine Approval – September 24, 2019 – The U.S. Food and Drug Administration announced the approval… Read more »

  • Clinical Insights: September 13, 2019

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Ibsrela® (tenapanor) – New Drug Approval – September 12, 2019 – Ardelyx, Inc., announced that the U.S. Food and Drug Administration has approved Ibsrela®… Read more »

  • Clinical Insights: August 29, 2019

    Welcome to RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Nourianz™ (istradefylline) – New Drug Approval – August 27, 2019 – The U.S. Food and Drug Administration approved Nourianz™ (istradefylline) tablets as an add-on treatment… Read more »

  • Clinical Insights: January 31, 2019

    Welcome to RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Tosymra™ (sumatriptan) – New Drug Approval – January 28, 2019 – Dr. Reddy’s Laboratories Ltd. and its subsidiary, Promius Pharma, LLC announced the approval of… Read more »

  • Clinical Insights – December 27, 2018

    Welcome to the December 27, 2018 edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. New Drug Approval  Ultomiris™ (ravulizumab)– New Drug Approval – December 21, 2018 – The U.S. Food and Drug Administration approved Ultomiris™ (ravulizumab) injection for the treatment of adult patients with paroxysmal… Read more »

  • Clinical Insights: November 7, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Lorbrena® (lorlatinib) – New Drug Approval – November 2, 2018 – The Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with… Read more »

  • Clinical Insights: October 10, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval TegsediTM (inotersen) – October 5, 2018 – Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc., announced that the U.S. Food and Drug… Read more »

  • Clinical Insights: August 30, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval AltrenoTM (tretinoin) – August 24, 2018 – Ortho Dermatologics, one of the largest prescription dermatology healthcare businesses in the world, announced that the U.S. Food and Drug… Read more »

  • Clinical Insights: August 3, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Mulpleta® (lusutrombopag) – July 31, 2018 – The Food and Drug Administration approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are… Read more »

  • Clinical Insights: July 19, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval SymtuzaTM (darunavir, cobicistat, emtricitabine and tenofovir alafenamide) – July 17, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration… Read more »